Download PDF

1. Company Snapshot

1.a. Company Description

Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally.The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase III clinical trial to control serum phosphorus in adult patients with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia.It is also developing RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease; and RDX020, an early-stage program in metabolic acidosis, a serious electrolyte disorder in patients with CKD.


The company has agreements with Kyowa Kirin in Japan, Fosun Pharmaceutical Industrial Development Co. Ltd.in China, and Knight Therapeutics, Inc.in Canada for the development and commercialization of tenapanor in their respective territories.


The company was formerly known as Nteryx, Inc.and changed its name to Ardelyx, Inc.in June 2008.


Ardelyx, Inc.was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

Show Full description

1.b. Last Insights on ARDX

Ardelyx's recent performance was negatively impacted by rising costs, including increased SG&A expenses and looming debt obligations. The company's limited pipeline and uncertain growth prospects, particularly with Xphozah's reimbursement issues and modest growth from Ibsrela, also contributed to the challenges. Additionally, the loss of Medicare Part D coverage for Xphozah limits revenue potential, despite the company's $750 million annual sales guidance.

1.c. Company Highlights

2. Ardelyx Q1 2026: Revenue Surge, Losses Narrow, and Growth Outlook

Ardelyx posted a 38% revenue jump to $93.4 million in Q1 2026, with IBSRELA contributing $70.1 million (+58%) and XPHOZAH $23.3 million (+19%). Net loss widened to $37.6 million, yet cash reserves climbed to $238.1 million. EPS slipped to –$0.15 versus the –$0.13 estimate, reflecting higher operating costs. The company trades at a negative P/E of –30.19 and a P/B of 11.79, indicating significant upside potential if earnings normalize.

Publication Date: 08:29

📋 Highlights
  • IBSRELA Revenue Growth: Achieved $70.1 million in Q1 2026, reflecting a 58% year-over-year increase, with a 2026 revenue guidance of $410–$430 million.
  • Total Product Revenue Expansion: Total product revenues reached $93.4 million, up 38% year-over-year, driven by strong performance across both IBSRELA and XPHOZAH.
  • XPHOZAH Momentum: Generated $23.3 million in revenue with a 19% year-over-year growth in paid prescriptions, supported by a patient-first strategy.
  • 2026 Financial Outlook: $238.1 million in cash reserves and a net loss of $37.6 million for Q1, with OpEx projected at $520 million for 2026 due to Phase III CIC trial ramp-up.
  • Long-Term IBSRELA Target: Maintains a $1 billion annual revenue goal for 2029, emphasizing commercial execution and market expansion despite competitive threats.

Financial Highlights

Revenue growth was driven by disciplined commercial execution, with total prescriptions and writers rising for IBSRELA. Despite a net loss, the firm’s cash position remains robust, and operating expenses are projected at $520 million for 2026, aligning with Phase III CIC study ramp‑up.

IBSRELA Momentum

IBSRELA’s 58% YoY revenue increase reflects successful penetration and pull‑through. The company reiterates 2026 guidance of $410–$430 million and targets $1 billion by 2029, citing “continued growth in demand” from Mike Raab. The IBSRELA Pharmacy Network is improving refill and reauthorization rates, boosting patient adherence.

XPHOZAH Growth

XPHOZAH’s paid prescriptions grew 19%, and the company maintains 2026 revenue guidance of $110–$120 million. Demand is bolstered by a patient‑first strategy and strong payer support. The firm highlighted quality of enrollment sites for its Phase III CIC trial, reinforcing confidence in sustained growth.

Pipeline & R&D

Ardelyx is advancing a Phase III CIC study, with enrollment on pace and expected to elevate operating expenses. Pediatric trials for IBSRELA are underway, offering potential for an additional six months of patent life. The firm’s pipeline remains a key driver for future upside.

Capital Allocation & Cash Position

With $238.1 million in cash and an extra $100 million in loan access, Ardelyx can fund growth and maintain financial strength. The company plans to prioritize IBSRELA expansion, pipeline investment, and operational efficiency while aiming for positive cash flow in the near term.

Guidance & Outlook

Ardelyx reiterated 2026 revenue guidance for IBSRELA ($410–$430 M) and XPHOZAH ($110–$120 M). Management expects Q2 to normalize after a storm‑affected Q1, with continued demand growth. The company’s long‑term objective remains a $1 billion IBSRELA annual revenue by 2029.

Analyst Q&A Highlights

Analysts probed IBSRELA’s market share versus Lilly’s GIPR agonist and the impact of CIC indications. Management emphasized physician engagement, field manager expansion, and the potential for off‑label use. They also confirmed that gross‑to‑net rates will peak in Q1 due to co‑pay dynamics but remain in the low‑30% range for the year.

3. NewsRoom

Card image cap

Ardelyx, Inc. (ARDX) Q1 2026 Earnings Call Transcript

May -01

Source: seekingalpha.com

Card image cap

Ardelyx (ARDX) Reports Q1 Loss, Beats Revenue Estimates

Apr -30

Source: zacks.com

Card image cap

Compared to Estimates, Ardelyx (ARDX) Q1 Earnings: A Look at Key Metrics

Apr -30

Source: zacks.com

Card image cap

Ardelyx Reports First Quarter 2026 Financial Results and Provides Business Update

Apr -30

Source: globenewswire.com

Card image cap

Ardelyx Announces Abstract Accepted for Poster Presentation at the NKF's Spring Clinical Meetings

Apr -27

Source: globenewswire.com

Card image cap

Ardelyx Announces Abstract Exploring IBS-C Treatment Patterns Accepted for Poster Presentation at Digestive Disease Week 2026

Apr -23

Source: globenewswire.com

Card image cap

Ardelyx Appoints Biopharmaceutical Veteran, Felecia W. Ettenberg, as Chief Legal Officer

Apr -20

Source: globenewswire.com

Card image cap

Ardelyx to Report First Quarter 2026 Financial Results on April 30, 2026

Apr -16

Source: globenewswire.com

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (8.97%)

6. Segments

Biopharmaceutical Products

Expected Growth: 8.97%

Ardelyx's biopharmaceutical products are driven by increasing demand for novel treatments, growing prevalence of chronic kidney disease and cardiorenal diseases, and the company's strong pipeline of innovative products, including tenapanor and RDX013. Additionally, strategic partnerships and collaborations are fueling growth, with a focus on expanding into new markets and indications.

7. Detailed Products

Tenapanor

Tenapanor is a minimally absorbed, oral, gut-restricted inhibitor of the sodium/hydrogen exchanger 3 (NHE3), in development for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic kidney disease (CKD).

RDX7675

RDX7675 is a novel, oral, non-absorbed phosphate binder in development for the treatment of hyperphosphatemia in patients with CKD on dialysis.

8. Ardelyx, Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

Ardelyx, Inc. has a moderate threat of substitutes due to the availability of alternative treatments for kidney disease and cardiovascular disease.

Bargaining Power Of Customers

Ardelyx, Inc. has a low bargaining power of customers due to the specialized nature of its products and the lack of alternative options for patients.

Bargaining Power Of Suppliers

Ardelyx, Inc. has a moderate bargaining power of suppliers due to the availability of multiple suppliers for raw materials and manufacturing services.

Threat Of New Entrants

Ardelyx, Inc. has a high threat of new entrants due to the growing demand for kidney disease and cardiovascular disease treatments and the availability of funding for biotech startups.

Intensity Of Rivalry

Ardelyx, Inc. operates in a highly competitive industry with several established players, leading to a high intensity of rivalry.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 25.13%
Debt Cost 8.26%
Equity Weight 74.87%
Equity Cost 8.26%
WACC 8.26%
Leverage 33.56%

11. Quality Control: Ardelyx, Inc. passed 2 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
Puma Biotechnology

A-Score: 5.4/10

Value: 7.3

Growth: 6.0

Quality: 8.6

Yield: 0.0

Momentum: 9.0

Volatility: 1.3

1-Year Total Return ->

View Full Report
Stock-Card
iTeos Therapeutics

A-Score: 4.9/10

Value: 7.8

Growth: 3.6

Quality: 4.4

Yield: 0.0

Momentum: 8.0

Volatility: 5.7

1-Year Total Return ->

View Full Report
Stock-Card
Ardelyx

A-Score: 4.4/10

Value: 6.8

Growth: 6.1

Quality: 4.7

Yield: 0.0

Momentum: 7.0

Volatility: 2.0

1-Year Total Return ->

View Full Report
Stock-Card
Ligand Pharmaceuticals

A-Score: 4.4/10

Value: 0.4

Growth: 4.4

Quality: 5.4

Yield: 0.0

Momentum: 10.0

Volatility: 6.0

1-Year Total Return ->

View Full Report
Stock-Card
Amylyx Pharmaceuticals

A-Score: 4.3/10

Value: 8.7

Growth: 3.6

Quality: 6.8

Yield: 0.0

Momentum: 5.0

Volatility: 2.0

1-Year Total Return ->

View Full Report
Stock-Card
Applied Therapeutics

A-Score: 3.1/10

Value: 8.0

Growth: 6.9

Quality: 3.5

Yield: 0.0

Momentum: 0.5

Volatility: 0.0

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

7.13$

Current Price

7.13$

Potential

-0.00%

Expected Cash-Flows